English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Although the prognosis of gastric cancer patients have a favorable progression, there are some patients with unusual patterns of locoregional and systemic recurrence. Therefore, a better understanding of early molecular events of the disease is needed. Current evidences demonstrate that long noncoding RNAs (lncRNAs) may be an important class of functional regulators involved in human gastric cancers development. Our previous studies suggest that  HOTAIR  contributes to gastric cancer development, and the overexpression of  HOTAIR  predicts a poor prognosis. In this study, we investigated the characteristic of the LncRNA FEZF1-AS1 in gastric cancer.    Methods  QRT-PCR was used to detect the expression of FEZF1-AS1 in gastric cancer tissues and cells. MTT assays, clonogenic survival assays and nude mouse xenograft model were used to examine the tumorigenesis function of FEZF1-AS1 in vitro and in vivo. Bioinformatics analysis were used to select downstream target genes of FEZF1-AS1. Cell cycle analysis, ChIP, RIP,RNA Pulldown assays were examined to dissect molecular mechanisms.    Results  In this study, we reported that  FEZF1-AS1 , a 2564 bp RNA, was overexpressed in gastric cancer, and upregulated  FEZF1-AS1  expression indicated larger tumor size and higher clinical stage; additional higher expression of  FEZF1-AS1  predicted poor prognosis. Further experiments revealed that knockdown  FEZF1-AS1  significantly inhibited gastric cancer cells proliferation by inducing G1 arrest and apoptosis, whereas endogenous expression  FEZF1-AS1  promoted cell growth. Additionally, RIP assay and RNA-pulldown assay evidenced that  FEZF1-AS1  could epigenetically repress the expression of P21 via binding with LSD1, the first discovered demethylase. ChIP assays demonstrated that LSD1 could directly bind to the promoter of P21, inducing H3K4me2 demethylation.    Conclusion  In summary, these data demonstrated that  FEZF1-AS1  could act as an “oncogene” for gastric cancer partly through suppressing P21 expression;  FEZF1-AS1  may be served as a candidate prognostic biomarker and target for new therapies of gastric cancer patients.    Electronic supplementary material  The online version of this article (doi:10.1186/s12943-017-0588-9) contains supplementary material, which is available to authorized users.

LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation